| Source: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Type: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk: by definition reduces risk of disease or cancer. Down Target direction of risk indicates lower cancer risk. ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral
|
| 4864- | Uro, | Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4876- | Uro, | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4314- | VitB1/Thiamine, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4327- | VitB1/Thiamine, | Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease |
| - | Study, | AD, | NA |
| 4056- | VitB12, | VitB6, | FA, | Vitamin B12, B6, or Folate and Cognitive Function in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis |
| - | Review, | AD, | NA |
| 4324- | VitB5, | Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson’s Disease Dementia |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4326- | VitB5, | Cerebral Vitamin B5 (D-Pantothenic Acid) Deficiency as a Potential Cause of Metabolic Perturbation and Neurodegeneration in Huntington’s Disease |
| - | in-vivo, | HD, | NA |
| 4325- | VitB5, | Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4323- | VitB5, | Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease |
| - | Study, | AD, | NA |
| 4052- | VitB6, | B-Vitamin Intake and Biomarker Status in Relation to Cognitive Decline in Healthy Older Adults in a 4-Year Follow-Up Study |
| - | Study, | AD, | NA |
| 4055- | VitB6, | VitD3, | Vitamin B6 and vitamin D deficiency co-occurrence in geriatric memory patients |
| - | Study, | AD, | NA |
| 4057- | VitB6, | VitB12, | FA, | Folate, Vitamin B6 and Vitamin B12 Intake and Mild Cognitive Impairment and Probable Dementia in the Women’s Health Initiative Memory Study |
| - | Study, | AD, | NA |
| 4062- | VitB6, | FA, | VitB12, | Vitamin B6, B9, and B12 Intakes and Cognitive Performance in Elders: National Health and Nutrition Examination Survey, 2011–2014 |
| - | Study, | AD, | NA |
| 4077- | VitB6, | FA, | VitB12, | VitD3, | VitE | Vitamin Supplementation as an Adjuvant Treatment for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4319- | VitC, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 3107- | VitC, | Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment |
| - | Review, | Var, | NA |
| 4350- | VitD3, | Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4320- | VitD3, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4618- | VitD3, | Vitamin D sensitizes cervical cancer to radiation-induced apoptosis by inhibiting autophagy through degradation of Ambra1 |
| - | in-vivo, | Cerv, | NA |
| 1739- | VitD3, | Effect of Vitamin D3 Supplements on Development of Advanced Cancer |
| - | Trial, | Var, | NA |
| 1740- | VitD3, | Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms |
| - | Review, | Var, | NA |
| 7068- | VitD3, | Vitamin D Reduces GABA-Positive Astrocytes in the 5xFAD Mouse Model of Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 4087- | VitE, | Vitamin E and Alzheimer's disease: what do we know so far? |
| - | Review, | AD, | NA |
| 2285- | VitK2, | New insights into vitamin K biology with relevance to cancer |
| - | Review, | Var, | NA |
| 4309- | VitK2, | Vitamins in the Prevention and Support Therapy of Neurodegenerative Diseases |
| - | Review, | NA, | NA |
| 1824- | VitK2, | Vitamin K and its analogs: Potential avenues for prostate cancer management |
| - | Review, | Pca, | NA |
| 1818- | VitK2, | New insights on vitamin K biology with relevance to cancer |
| - | Review, | Var, | NA |
| 1825- | VitK2, | Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial |
| - | Analysis, | Pca, | NA |
| 1830- | VitK2, | Vitamin K Intake and Risk of Lung Cancer: The Japan Collaborative Cohort Study |
| - | Study, | Lung, | NA |
| 1759- | WBV, | Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study |
| - | Study, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:785 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid